Consistent with this, IHC analysis of primary human CRC patient samples confirm high Bcl-xL expression in CRC tumors harvested from both primary and metastatic sites as well as the near absence of Bcl-2 expression, which could serve as a resistance factor. Here, BCL2L1 is linked to colorectal carcinoma.